CD20 drugs for Multiple Sclerosis
8 tracked CD20 drugs in the Multiple Sclerosis race. The class explanation lives on the CD20 page; the full indication pipeline across every mechanism is on the Multiple Sclerosis page.
4 approved / phase 44 Phase 3
Head-to-head evidence: ABP 692 vs Divozilimab · ABP 692 vs Ocrelizumab · ABP 692 vs Ofatumumab · ABP 692 vs Ublituximab · BCD-281 vs Divozilimab · BCD-281 vs Ocrelizumab